2026-04-06 12:36:40 | EST
Earnings Report

Is International (IBM) Stock a Good Buy in 2026 | IBM (International Business Machines Corporation) Q4 2025 Earnings: Posts $4.52 EPS to beat consensus estimates - Turnaround Phase

IBM - Earnings Report Chart
IBM - Earnings Report

Earnings Highlights

EPS Actual $4.52
EPS Estimate $4.3628
Revenue Actual $67536000000.0
Revenue Estimate ***
Free US stock screening tools combined with expert analysis to help you identify undervalued companies with strong growth potential. We use sophisticated algorithms and human expertise to surface opportunities that might otherwise go unnoticed. International Business Machines Corporation (IBM) has released its officially verified the previous quarter earnings results, reporting a quarterly earnings per share (EPS) of $4.52 and total quarterly revenue of $67.536 billion. The results cover the final quarter of the prior fiscal year, reflecting performance across the company’s four core operating segments: hybrid cloud infrastructure, enterprise AI solutions, global business consulting, and legacy on-premise technology. This release comes

Executive Summary

International Business Machines Corporation (IBM) has released its officially verified the previous quarter earnings results, reporting a quarterly earnings per share (EPS) of $4.52 and total quarterly revenue of $67.536 billion. The results cover the final quarter of the prior fiscal year, reflecting performance across the company’s four core operating segments: hybrid cloud infrastructure, enterprise AI solutions, global business consulting, and legacy on-premise technology. This release comes

Management Commentary

During the public the previous quarter earnings call, IBM leadership highlighted key drivers of the quarter’s performance, noting that solid growth in AI-related revenue and hybrid cloud subscription sales contributed the largest share of top-line expansion during the period. Leadership noted that adoption of the company’s watsonx AI platform, which is built to serve heavily regulated industries including finance, healthcare, and public sector government agencies, accelerated during the quarter, with a growing number of enterprise clients signing multi-year deployment and service contracts. Management also acknowledged that softer demand for legacy on-premise infrastructure products partially offset growth in newer, higher-growth segments, a dynamic the company has been addressing through ongoing portfolio restructuring and targeted divestment of non-core assets over recent periods. The increasing availability of commodity data allows equity traders to track potential supply chain effects. Shifts in raw material prices often precede broader market movements.

Forward Guidance

In terms of future outlook, IBM management provided cautious, high-level guidance for upcoming operating periods, avoiding specific numerical revenue or EPS targets in line with the company’s recent standard disclosure practices. Leadership noted that ongoing investments in AI research and development, global partner ecosystem expansion, and expanded go-to-market resources for high-margin segments would likely remain top operational priorities in the near term. Management also flagged potential headwinds that could impact upcoming performance, including uneven enterprise IT spending patterns in certain regional markets, ongoing supply chain volatility for select hardware components, and growing competitive pressure in the enterprise cloud and AI spaces. The company noted that it will continue to balance targeted growth investments with cross-operational cost optimization efforts to support margin stability as it scales its newer business lines. Some investors track short-term indicators to complement long-term strategies. The combination offers insights into immediate market shifts and overarching trends.

Market Reaction

Following the public release of the previous quarter earnings, trading activity in IBM shares saw above-average volume in the sessions immediately after the announcement, as market participants digested the newly released performance data. Analyst notes published in the days after the release have focused heavily on the pace of AI revenue growth, with many industry observers identifying that metric as a key indicator of the long-term success of IBM’s ongoing strategic pivot. Some analysts have noted that the steady growth in recurring revenue from cloud and AI subscriptions could support greater long-term revenue visibility for the firm, while others have pointed to the ongoing drag from declining legacy segment revenue as a factor that may influence investor sentiment in the near term. Based on available market data, IBM shares traded in a relatively narrow range in the first two sessions following the release, suggesting that the Q4 results were largely priced in by investors ahead of the official announcement. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Correlating global indices helps investors anticipate contagion effects. Movements in major markets, such as US equities or Asian indices, can have a domino effect, influencing local markets and creating early signals for international investment strategies.
Article Rating 86/100
3829 Comments
1 Hermenia Returning User 2 hours ago
Real-time US stock futures and options market analysis to understand broader market sentiment and directional bias. We provide comprehensive derivatives analysis that often provides early signals for equity market movements.
Reply
2 Kareme Senior Contributor 5 hours ago
Early trading suggests a bullish bias, but watch afternoon sessions closely.
Reply
3 Danneth Insight Reader 1 day ago
This feels like a beginning and an ending.
Reply
4 Aadhya Legendary User 1 day ago
Pure wizardry, no kidding. 🪄
Reply
5 Andriana Returning User 2 days ago
Overall liquidity appears sufficient, but investors should remain mindful of potential market corrections.
Reply
Disclaimer: Not investment advice. Earnings data is based on company reports and analyst estimates. Past performance does not guarantee future results.